Search clinical trials for: chimeric antigen receptor (CAR) T cell therapy

Total 1176 results

Chinese PLA General Hospital

Recruiting

CAR-T-19 Cells for Patients With CD19+ Relapse/Refractory B-ALL

CD19+ Relapse/Refractory B-ALL

China
Shenzhen University General Hospital

Recruiting

CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer (CAR-T)

Advanced Pancreatic Carcinoma

China
University of Colorado, Denver

Recruiting

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

Non-Hodgkin Lymphoma

United States
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD123-Targeted CAR-T Therapy for Relapsed/Refractory Acute Myeloid Leukemia

Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital; Beijing Lu Daopei Hospital

Recruiting

CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Lymphoma | Leukemia | Multiple Myeloma of Bone (Diagnosis)

China
Shanghai Unicar-Therapy Bio-medicine Technology...
The First Affiliated Hospital of Soochow University

Recruiting

CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia

B-cell Acute Lymphocytic Leukemia

China
Marcela V. Maus, M.D.,Ph.D.

Completed

CAR-37 T Cells In Hematologic Malignancies

Lymphoma | Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Leukemia | Lymphoma, T-Cell | Hematologic Malignancy

United States
Sheba Medical Center

Unknown

T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies

Acute Lymphoblastic Leukemia, B-precursor | Non-Hodgkin Lymphoma, B-cell

Israel
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.; Union Stem cell & gene engineering Co.LTD

Completed

CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, Adult B-Cell | Acute Lymphoblastic Leukaemia Recurrent

China
Tianjin Mycure Medical Technology Co., Ltd

Unknown

CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.

B-cell Acute Lymphoblastic Leukemia

China
Seattle Children's Hospital
The Evan Foundation; Ben Towne Center for Childhood Cancer Research

Active, not recruiting

Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01

Neuroblastoma | Ganglioneuroblastoma

United States
Beijing Immunochina Medical Science & Technology...

Not yet recruiting

Donor-derived CAR-T Cells in the Treatment of AML Patients

AML

China
He Huang
Yake Biotechnology Ltd.

Recruiting

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

Relapsed and Refractory | Lymphoid Hematological Malignancies

China
University College, London

Not yet recruiting

Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma (MAGNETO)

Neuroblastoma
Shenzhen University General Hospital

Recruiting

CD7 CAR-T Cells in T-cell Lymphoma/Leukemia

T Lymphoblastic Leukemia/Lymphoma

China
Peking University

Not yet recruiting

Novel GPC3 CAR-T Cell Therapy for Hepatocellular Carcinoma
Beijing Immunochina Medical Science & Technology...

Not yet recruiting

Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia

Leukemia
Beijing Immunochina Medical Science & Technology...

Recruiting

Clinical Trial to Evaluate the Safety and Efficacy of IM92 CAR-T Cells Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma

Gastric Cancer | Pancreatic Cancer | Advanced Solid Tumors | Esophagogastric Junction Cancer

China
Shenzhen University General Hospital

Recruiting

B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma

Multiple Myeloma | Refractory Multiple Myeloma | Relapse Multiple Myeloma

China
iCell Gene Therapeutics
Peking University Shenzhen Hospital; iCAR Bio Therapeutics Ltd.

Recruiting

Non-gene Edited Anti-CD7 CAR T Cells for Relapsed/Refractory T Cell Malignances

T-cell Acute Lymphoblastic Leukemia | T-cell Non-Hodgkin Lymphoma | T-cell Acute Lymphoblastic Lymphoma

China
Chongqing Precision Biotech Co., Ltd

Recruiting

BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma

Multiple Myeloma | Multiple Myeloma in Relapse | Neoplasm, Plasma Cell

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Lymphoma | Leukemia | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia, B-Cell

China
University of Colorado, Denver

Active, not recruiting

Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Non Hodgkin Lymphoma

United States
Institute of Hematology & Blood Diseases Hospital
Juventas Cell Therapy Ltd.

Completed

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

Relapse | Lymphomas Non-Hodgkin's B-Cell

China
Hebei Senlang Biotechnology Inc., Ltd.
Hebei Yanda Ludaopei Hospital

Unknown

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Myelocytic Leukemia

Acute Myelocytic Leukemia

China
Chinese PLA General Hospital

Recruiting

Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL

Non-hodgkin Lymphoma,B Cell

China
University of Florida
United States Department of Defense; AM Rosen Foundation

Recruiting

Phase I Study of IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma (IMPACT) (IMPACT)

Glioblastoma | Glioblastoma Multiforme

United States
Mari Dallas

Recruiting

Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation

United States
Medical College of Wisconsin

Not yet recruiting

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Multiple Myeloma
Kang YU
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

Hepatocellular Carcinoma | B Cell Lymphoma | Pancreatic Carcinoma | Myeloma | B Cell Leukemia | Adenocarcinoma of Esophagogastric Junction

China
Caribou Biosciences, Inc.

Enrolling by invitation

Long-Term Follow-up Study (LTFS)

Lymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Hematologic Malignancy | Relapsed/Refractory Multiple Myeloma | Relapsed/Refractory Acute Myeloid Leukemia | Relapsed Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin's Lymphoma

United States
Mehrdad Abedi, MD
National Cancer Institute (NCI)

Recruiting

Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma

United States
Beijing GoBroad Hospital

Not yet recruiting

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

Refractory/Relapsed Acute Myeloid Leukaemia

China
The First Affiliated Hospital of Soochow University

Recruiting

CD19 CAR-T Consolidation Therapy for Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia, Adult B-Cell

China
Hrain Biotechnology Co., Ltd.
Shanghai Zhongshan Hospital

Recruiting

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

B-cell Non-Hodgkin's Lymphoma

China
Children's National Research Institute

Recruiting

Adoptive T Lymphocyte Administration for Chronic Norovirus Treatment in Immunocompromised Hosts (ATLANTIC)

Viral Infection | Hematopoietic Stem Cell Transplantation (HSCT) | Primary Immunodeficiency Disorders (PID)

United States
Celgene

Recruiting

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Neoplasms

United States, Belgium, Spain, Switzerland, Canada, France, Germany, Japan, Finland, United Kingdom, Austria, Italy, Netherlands, Norway, Sweden
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) (CARPASCIO)

Non-Hodgkin's Lymphoma | B-Cell ALL | B-Cell CLL

United States
Memorial Sloan Kettering Cancer Center
Actinium Pharmaceuticals

Recruiting

Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Diffuse Large B-cell Lymphoma | B-ALL | DLBCL | DLBCL, Nos Genetic Subtypes | B ALL | Dlbcl-Ci | DLBCL Unclassifiable | DLBCL Activated B-Cell Type | DLBCL Germinal Center B-Cell Type | HGBL | HGBL, Nos

United States
Hebei Yanda Ludaopei Hospital
Gracell Biotechnology Ltd.

Unknown

A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM

Multiple Myeloma

China
The Second Hospital of Nanjing Medical University

Unknown

Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC

Primary Hepatocellular Carcinoma
Viracta Therapeutics, Inc.

Recruiting

An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)

EBV Related Non-Hodgkin's Lymphoma | Epstein-Barr Virus Associated Lymphoproliferative Disorder | EBV-Related PTLD | EBV Associated Lymphoma | EBV-Positive DLBCL, NOS | EBV Related PTCL, NOS

United States, Spain, Italy, United Kingdom, Singapore, Taiwan, Korea, Republic of, Germany, Canada, Brazil, Australia, France, Malaysia, Hong Kong, Israel
Hrain Biotechnology Co., Ltd.
Second Affiliated Hospital of Nanchang University

Recruiting

To Evaluate the Safety and Efficacy of Human CD19 Targeted DASH CAR-T Cells Injection for Subjects With R/R B-ALL

B-cell Acute Lymphoblastic Leukemia

China
First Affiliated Hospital of Wenzhou Medical University
Shanghai First Song Therapeutics Co., Ltd

Not yet recruiting

The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases

Systemic Sclerosis | Sjogren's Syndrome | Antiphospholipid Syndrome | ANCA Associated Vasculitis | Systemic Lupus Erythematosus (SLE) | Inflammatory Myopathy

China
Chongqing Precision Biotech Co., Ltd

Recruiting

Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease

Systemic Scleroderma | Dermatomyositis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Sjogren's Syndrome | SLE (Systemic Lupus)

China
Changhai Hospital
UTC Therapeutics Inc.

Recruiting

Anti-CD70 CAR-T Cell Injection in Patients With CD70-positive Advanced Urologic Neoplasms

CD70-positive Advanced Urologic Neoplasms

China
St. Jude Children's Research Hospital

Recruiting

Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors

Glioblastoma | Central Nervous System Neoplasms | High Grade Glioma | Ependymoma | Medulloblastoma | Diffuse Midline Glioma, H3 K27M-Mutant | Atypical Teratoid/Rhabdoid Tumor

United States
Zhejiang University

Recruiting

Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica

Neuromyelitis Optica

China
Zhejiang University

Recruiting

Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of Refractory Myasthenia Gravis

Myasthenia Gravis

China

Search clinical trials for: chimeric antigen receptor (CAR) T cell therapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations